Cpad

1840 E River Rd Ste 100
Tucson, AZ 85718

Cpad is a Tucson-based organization that operates a variety of active consortia programs focused on advancing research and innovation in various medical fields, including Alzheimer's disease, Parkinson's disease, rare neurodegenerative diseases, and more. They also offer training courses and platforms for sharing knowledge and data, with the aim of accelerating the development of therapeutics and improving patient outcomes.

With a breadth of expertise and a commitment to collaboration, Cpad brings together experts from different disciplines to tackle complex medical challenges and drive progress in the field of healthcare. Through their programs and initiatives, they aim to provide evidence-based solutions and contribute to the development of new treatments and therapies for a range of diseases and conditions.

Generated from the website

Own this business?
See a problem?

You might also like

Psychiatrists and psychoanalysts, Medical research

Critical Path Institute

Critical Path Institute, founded in 2005 in Tucson, Arizona, is an independent, non-profit organization dedicated to bringing scientists from the FDA, industry, and academia together to improve the path for innovative new drugs, diagnostic tests and devices to reach patients in need.Based in Arizona with offices in Tucson, Phoenix, and Rockville, Maryland, C-Path relies on three basic tenets in its approach to drug development: faster, safer and smarter. Our programs address scientific, safety and educational aspects of medical product development in support of the FDA's Critical Path Initiative. The overall goal of the Critical Path Initiative is to modernize the scientific process through which a potential human drug, biological product, or medical device is tested and developed. Our programs were developed with detailed input and participation from scientists from the FDA, industry and academia.Our contributors include key organizations and individuals from the public and private sectors at the local, regional and national levels. Since 2005, over $20 million in grants and $10 million in contributions has been received to support C-Path's work. In order to serve as a neutral and trusted third party for collaborators, C-Path does not accept monies from organizations that develop products regulated by the FDA or that would create a real or perceived conflict of interest. C-Path manages industrial consortia of companies willing to share pre-competitive knowledge and work in support of projects that are identified as high priority by the FDA and are in the interest of public health.

Partial Data by Infogroup (c) 2025. All rights reserved.